|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
|
CN103435581B
(zh)
*
|
2004-03-16 |
2015-08-19 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
ATE491700T1
(de)
*
|
2005-09-08 |
2011-01-15 |
Boehringer Ingelheim Int |
KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-
|
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
JP5323684B2
(ja)
|
2006-05-04 |
2013-10-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
多形体
|
|
JP5384343B2
(ja)
*
|
2006-08-15 |
2014-01-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、ｓｇｌｔ阻害剤としてのそれらの使用及びそれらの製造方法
|
|
JP5372759B2
(ja)
*
|
2006-09-21 |
2013-12-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
|
|
US8283326B2
(en)
*
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
CA2679310A1
(en)
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
PL2200606T3
(pl)
|
2007-09-10 |
2018-08-31 |
Janssen Pharmaceutica, N.V. |
Sposób wytwarzania związków użytecznych jako inhibitory SGLT2
|
|
CA2706018C
(en)
|
2007-11-30 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo [3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
|
|
WO2009096455A1
(ja)
*
|
2008-01-31 |
2009-08-06 |
Astellas Pharma Inc. |
脂肪性肝疾患の治療用医薬組成物
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
AU2009270936B2
(en)
|
2008-07-15 |
2014-12-18 |
Theracos, Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
AU2009286380B2
(en)
|
2008-08-28 |
2011-09-15 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
|
CA2736304A1
(en)
|
2008-09-08 |
2010-03-11 |
Boehringer Ingelheim International Gmbh |
Pyrazolopyrimidines and their use for the treatment of cns disorders
|
|
JP2012502081A
(ja)
|
2008-09-10 |
2012-01-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連症状の治療のための組み合わせ治療
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
CN103497192B
(zh)
|
2008-12-09 |
2015-09-23 |
吉里德科学公司 |
Toll样受体调节剂
|
|
TWI508965B
(zh)
|
2008-12-23 |
2015-11-21 |
Boehringer Ingelheim Int |
有機化合物的鹽形式
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
AU2016213789B2
(en)
*
|
2009-02-13 |
2018-01-18 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
|
|
US20110046076A1
(en)
|
2009-02-13 |
2011-02-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
JP5896276B2
(ja)
*
|
2009-02-13 |
2016-03-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１型糖尿病、２型糖尿病、耐糖能障害又は高血糖の治療用ｓｇｌｔ−２阻害薬
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
US20110014284A1
(en)
|
2009-02-13 |
2011-01-20 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
GEP20146098B
(en)
|
2009-03-31 |
2014-05-27 |
Boehringer Ingelheim Int |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their usage as pde9a modulators
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
WO2011003976A1
(en)
|
2009-07-10 |
2011-01-13 |
Janssen Pharmaceutica Nv |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL] BENZENE
|
|
EP2480559B1
(en)
|
2009-09-21 |
2013-07-03 |
Gilead Sciences, Inc. |
Processes and intermediates for the preparation of 1'-cyano-carbanucleoside analogs
|
|
CA2775961C
(en)
*
|
2009-09-30 |
2017-11-07 |
Boehringer Ingelheim International Gmbh |
Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
|
DK2486029T3
(en)
|
2009-09-30 |
2015-08-24 |
Boehringer Ingelheim Int |
Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
|
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
|
RS55909B1
(sr)
|
2009-10-14 |
2017-09-29 |
Janssen Pharmaceutica Nv |
Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
|
|
NZ599945A
(en)
|
2009-11-02 |
2014-05-30 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
KR20190071840A
(ko)
|
2009-11-27 |
2019-06-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2552442A1
(en)
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
|
MX366325B
(es)
|
2010-05-05 |
2019-07-05 |
Boehringer Ingelheim Int |
Terapia de combinacion.
|
|
BR112012028857B1
(pt)
|
2010-05-11 |
2021-02-09 |
Janssen Pharmaceutica Nv |
Composições farmacêuticas administráveis por via oral que compreendem derivados de 1- (beta-d glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt
|
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
PT2595980E
(pt)
|
2010-07-22 |
2014-11-27 |
Gilead Sciences Inc |
Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
|
|
BR112013003097B1
(pt)
|
2010-08-12 |
2021-03-16 |
Boehringer Ingelheim International Gmbh |
6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
|
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
|
CA2813671A1
(en)
|
2010-11-02 |
2012-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
|
AU2012241897C1
(en)
|
2011-04-13 |
2017-05-11 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
EA201301354A1
(ru)
|
2011-06-03 |
2014-05-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
|
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
KR101985384B1
(ko)
|
2011-07-15 |
2019-06-03 |
베링거 인겔하임 인터내셔날 게엠베하 |
치환된 퀴나졸린, 이의 제조 및 약제학적 조성물에서의 이의 용도
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
BR112014027884A2
(pt)
|
2012-05-09 |
2017-06-27 |
Boehringer Ingelheim Int |
combinações farmacêuticas para tratamento de distúrbios metabólicos
|
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
|
JP6218811B2
(ja)
|
2012-05-14 |
2017-10-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
PL2981269T3
(pl)
|
2013-04-04 |
2024-02-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Leczenie zaburzeń metabolicznych u zwierząt koniowatych
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
TR201901110T4
(tr)
|
2013-04-05 |
2019-02-21 |
Boehringer Ingelheim Int |
Empagliflozinin terapötik kullanımları.
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
DK2986304T3
(da)
|
2013-04-18 |
2022-04-04 |
Boehringer Ingelheim Int |
Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf.
|
|
ES2605886T3
(es)
|
2013-09-27 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Derivados de glucopiranosilo y sus usos en medicina
|
|
ES2859905T3
(es)
|
2013-12-17 |
2021-10-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
|
|
US10603300B2
(en)
*
|
2014-01-23 |
2020-03-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in canine animals
|
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
|
ES2811261T3
(es)
*
|
2014-04-01 |
2021-03-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabólicos en animales equinos
|
|
CN103965020B
(zh)
*
|
2014-05-06 |
2015-09-09 |
启东东岳药业有限公司 |
制备5-碘-2-溴苄醇的方法
|
|
JP6522732B2
(ja)
|
2014-07-11 |
2019-05-29 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖを治療するためのトール様受容体の調節因子
|
|
KR20190125537A
(ko)
|
2014-09-16 |
2019-11-06 |
길리애드 사이언시즈, 인코포레이티드 |
톨-유사 수용체 조정제의 고체 형태
|
|
ES2991763T3
(es)
|
2014-09-25 |
2024-12-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de combinación de inhibidores de SGLT2 y agonistas de dopamina para la prevención de trastornos metabólicos en animales equinos
|
|
TWI740546B
(zh)
*
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
|
KR20220070057A
(ko)
|
2015-03-09 |
2022-05-27 |
인테크린 테라퓨틱스, 아이엔씨. |
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법
|
|
CN107995862B8
(zh)
|
2015-08-27 |
2021-12-03 |
勃林格殷格翰维特梅迪卡有限公司 |
包含sglt-2抑制剂之液态药物组合物
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
PL3349758T3
(pl)
|
2015-09-16 |
2022-09-12 |
Gilead Sciences, Inc. |
Sposoby leczenia zakażeń wirusami arenaviridae
|
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
|
AU2017357589B2
(en)
|
2016-11-10 |
2023-05-11 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
KR102460968B1
(ko)
|
2017-03-14 |
2022-11-01 |
길리애드 사이언시즈, 인코포레이티드 |
고양이 코로나바이러스 감염의 치료 방법
|
|
SG11201909046XA
(en)
|
2017-04-03 |
2019-10-30 |
Coherus Biosciences Inc |
PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
|
|
JP2020518578A
(ja)
|
2017-05-01 |
2020-06-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
（Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
|
|
CA3077489A1
(en)
|
2017-07-11 |
2019-01-17 |
Gilead Sciences, Inc. |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
|
UY38969A
(es)
|
2019-11-28 |
2021-05-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
|
|
CN118766947A
(zh)
|
2020-01-27 |
2024-10-15 |
吉利德科学公司 |
用于治疗SARS CoV-2感染的方法
|
|
CN118615450A
(zh)
|
2020-02-17 |
2024-09-10 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
|
|
MX2022010748A
(es)
|
2020-03-06 |
2022-09-23 |
Vertex Pharma |
Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
|
|
TWI890963B
(zh)
|
2020-03-12 |
2025-07-21 |
美商基利科學股份有限公司 |
1'-氰基核苷之製備方法
|
|
CN115362004A
(zh)
|
2020-04-06 |
2022-11-18 |
吉利德科学公司 |
1’-氰基取代的碳核苷类似物的吸入制剂
|
|
ES3041698T3
(en)
|
2020-05-29 |
2025-11-13 |
Gilead Sciences Inc |
Remdesivir for the treatment of viral infections
|
|
JP2023531524A
(ja)
|
2020-06-24 |
2023-07-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
１’－シアノヌクレオシド類似体及びその使用
|
|
IL300453A
(en)
|
2020-08-27 |
2023-04-01 |
Gilead Sciences Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
|
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
|
CA3223537A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
|
JP2024525981A
(ja)
|
2021-07-28 |
2024-07-12 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用
|
|
CA3242880A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
COMBINATION OF OBITECRAPIB AND SGLT2 INHIBITOR
|
|
TW202525810A
(zh)
|
2022-03-02 |
2025-07-01 |
美商基利科學股份有限公司 |
用於治療病毒感染的化合物及方法
|
|
JP2025516857A
(ja)
|
2022-05-25 |
2025-05-30 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
Ｓｇｌｔ－２阻害薬を含む水性医薬組成物
|
|
AU2024233233A1
(en)
|
2023-03-06 |
2025-09-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
KR20250172894A
(ko)
|
2023-04-24 |
2025-12-09 |
뉴암스테르담 파마 비.브이. |
비정질 오비세트라피브 및 sglt2 억제제 조합
|
|
WO2024240633A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
|
|
TW202508593A
(zh)
|
2023-05-24 |
2025-03-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
|
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|